Brokerages Set 10x Genomics (NASDAQ:TXG) Target Price at $13.65

10x Genomics (NASDAQ:TXG) has received a consensus rating of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $13.6538.

A number of analysts recently commented on the stock. Barclays reiterated an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, September 27th. Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research report on Monday, August 11th. Zacks Research lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Piper Sandler assumed coverage on shares of 10x Genomics in a research report on Thursday, September 11th. They set a “neutral” rating and a $15.00 price target for the company.

10x Genomics Stock Down 0.9%

TXG stock opened at $12.64 on Thursday. The firm has a 50 day moving average of $13.13 and a 200 day moving average of $11.02. The stock has a market capitalization of $1.57 billion, a PE ratio of -18.06 and a beta of 2.05. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $20.92.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock valued at $539,865. 10.03% of the stock is owned by insiders.

Institutional Investors Weigh In On 10x Genomics

A number of hedge funds and other institutional investors have recently made changes to their positions in TXG. Allworth Financial LP grew its stake in shares of 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after purchasing an additional 1,364 shares during the period. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC grew its stake in shares of 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after purchasing an additional 2,409 shares during the period. Whittier Trust Co. acquired a new stake in shares of 10x Genomics during the 1st quarter worth approximately $41,000. Finally, True Wealth Design LLC grew its stake in shares of 10x Genomics by 1,552.5% during the 2nd quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after purchasing an additional 3,369 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.